COVID player and Pfizer-partnered Valneva eyes $100M Nasdaq IPO

cafead

Administrator
Staff member
  • cafead   Apr 12, 2021 at 11:42: PM
via French biotech Valneva, which has developed a lineup of traveler vaccines and is starting a late-stage COVID vax effort, is seeking to level up to the Nasdaq with a $100 million IPO.

article source
 

<